Clear Harbor Asset Management LLC Takes $1.66 Million Position in Baxter International Inc. $BAX

Posted by Brian Himes on Aug 23rd, 2026

Clear Harbor Asset Management LLC acquired a new stake in Baxter International Inc. (NYSE:BAX – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 78,009 shares of the medical instruments supplier’s stock, valued at approximately $1,663,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BAX. Basepoint Wealth LLC purchased a new stake in shares of Baxter International during the 4th quarter worth approximately $26,000. Imprint Wealth LLC purchased a new position in Baxter International in the 3rd quarter valued at approximately $27,000. MUFG Securities EMEA plc purchased a new position in Baxter International in the 2nd quarter valued at approximately $46,000. Los Angeles Capital Management LLC acquired a new position in Baxter International during the fourth quarter worth $46,000. Finally, Versant Capital Management Inc raised its holdings in Baxter International by 552.2% during the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,043 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Weiss Ratings raised shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Zacks Research upgraded Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. The Goldman Sachs Group upped their target price on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Barclays raised their price target on Baxter International from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Finally, Wall Street Zen raised Baxter International from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $22.45.

Check Out Our Latest Analysis on Baxter International

Baxter International Stock Performance

NYSE:BAX opened at $26.37 on Friday. The company has a market cap of $13.63 billion, a P/E ratio of -12.74, a P/E/G ratio of 3.98 and a beta of 0.60. The firm’s 50 day moving average is $23.62 and its two-hundred day moving average is $20.36. Baxter International Inc. has a fifty-two week low of $15.73 and a fifty-two week high of $30.00. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39.

Baxter International (NYSE:BAX – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.59 earnings per share. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Analysts expect that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be paid a dividend of $0.01 per share. The ex-dividend date is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -1.93%.

Key Baxter International News

Here are the key news stories impacting Baxter International this week:

Positive Sentiment: Higher earnings forecasts: Zacks Research raised its FY2026 EPS estimate to $2.02 from $1.83 and its FY2027 estimate to $2.00 from $1.90. The FY2026 forecast is close to the broader consensus estimate of $2.04, suggesting improving expectations for Baxter’s profitability.
Positive Sentiment: Several quarterly upgrades: Zacks increased its estimates for Q1 2027 EPS to $0.42 from $0.38, Q2 2027 EPS to $0.47 from $0.40, and Q2 2028 EPS to $0.51 from $0.45. These revisions indicate stronger projected earnings in multiple future periods.
Neutral Sentiment: Analyst stance remains cautious: Despite the higher full-year estimates, Zacks maintained a “Hold” rating on BAX. The research firm’s FY2028 EPS forecast of $2.11 was also slightly reduced from $2.13, while its Q3 2027 and Q4 2026 estimates were trimmed to $0.52 and $0.60, respectively.
Negative Sentiment: Reported cybersecurity incident: A report alleges that the ShinyHunters hacking group leaked 7.1 million Baxter International records. If confirmed, the incident could create legal, remediation, regulatory and reputational costs, although the available report does not specify the type or sensitivity of the exposed information. ShinyHunters Leaks 7.1 Million Baxter International Records

Baxter International Company Profile

(Free Report)

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.